drugset / Trial / NCT01887002

Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT01887002 ↗

Phase 2 Terminated 39 enrolled Ono Pharma USA Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective is to evaluate whether ONO-2952 modulates visceral pain perception produced by rectal distention in female patients with IBS-D

Timeline

Start
2013-06
Primary completion
2015-01
Completion
—

Outcome

Outcome not reported

Stopped (Enrollment): “The study was terminated due to slow accrual of subjects.”

Drugs

EvaluationDrugModalityDoseRoute
Subject ONO-2952 Small molecule — —